|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
DE69535243T2
(de)
|
1994-07-13 |
2007-05-10 |
Chugai Seiyaku K.K. |
Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
|
|
GB9716557D0
(en)
|
1997-08-06 |
1997-10-08 |
Glaxo Group Ltd |
Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
|
|
DK1069185T3
(da)
|
1998-04-03 |
2011-06-27 |
Chugai Pharmaceutical Co Ltd |
Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof
|
|
DK1071700T3
(da)
|
1998-04-20 |
2010-06-07 |
Glycart Biotechnology Ag |
Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
CA2704600C
(en)
|
1999-04-09 |
2016-10-25 |
Kyowa Kirin Co., Ltd. |
A method for producing antibodies with increased adcc activity
|
|
FR2807767B1
(fr)
|
2000-04-12 |
2005-01-14 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-d
|
|
CA2512729C
(en)
|
2003-01-09 |
2014-09-16 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
DE10359795A1
(de)
|
2003-12-19 |
2005-07-21 |
Bayer Technology Services Gmbh |
Strangverdampfervorrichtung
|
|
EP2301528B1
(en)
*
|
2004-08-18 |
2013-04-03 |
Kadmon Corporation, LLC |
Use of FTS for treating malignant disorders
|
|
US20110104256A1
(en)
*
|
2008-03-25 |
2011-05-05 |
Yaolin Wang |
Methods for treating or preventing colorectal cancer
|
|
BRPI0911926A2
(pt)
|
2008-08-05 |
2020-08-18 |
Toray Industries, Inc |
composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo.
|
|
EP2711018A1
(en)
|
2009-06-22 |
2014-03-26 |
MedImmune, LLC |
Engineered Fc regions for site-specific conjugation
|
|
EP2480671B8
(en)
|
2009-09-22 |
2015-10-28 |
ProBioGen AG |
Process for producing molecules containing specialized glycan structures
|
|
WO2011090738A2
(en)
|
2009-12-29 |
2011-07-28 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
|
CA2788545C
(en)
|
2010-02-04 |
2019-03-26 |
Toray Industries, Inc. |
Pharmaceutical composition for treating and/or preventing cancer
|
|
RU2603742C2
(ru)
|
2010-02-04 |
2016-11-27 |
Торэй Индастриз, Инк. |
Фармацевтическая композиция для лечения и/или профилактики рака
|
|
US9115200B2
(en)
|
2010-02-04 |
2015-08-25 |
Toray Industries, Inc. |
Pharmaceutical composition for treating cancer using a monoclonal antibody having immunological reactivity with CAPRIN-1
|
|
DK2532680T3
(da)
|
2010-02-04 |
2015-07-20 |
Toray Industries |
Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
|
|
HUE040012T2
(hu)
|
2010-02-04 |
2019-02-28 |
Toray Industries |
Gyógyászati ágens rák kezelésére és/vagy megelõzésére
|
|
DK2532366T3
(da)
|
2010-02-04 |
2017-01-02 |
Toray Industries |
Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
|
|
WO2011103196A1
(en)
|
2010-02-17 |
2011-08-25 |
Amgen Inc. |
Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
|
|
JP2013528357A
(ja)
|
2010-03-29 |
2013-07-11 |
ザイムワークス，インコーポレイテッド |
強化又は抑制されたエフェクター機能を有する抗体
|
|
PT2740489T
(pt)
|
2011-08-04 |
2017-01-10 |
Toray Industries |
Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático
|
|
PT2740796T
(pt)
|
2011-08-04 |
2017-07-26 |
Toray Industries |
Composição farmacêutica para o tratamento e/ou profilaxia de cancro
|
|
EP2740794B1
(en)
|
2011-08-04 |
2018-04-04 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prophylaxis of cancer
|
|
US9181348B2
(en)
|
2011-08-04 |
2015-11-10 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prophylaxis of cancer
|
|
PL2740793T3
(pl)
|
2011-08-04 |
2018-04-30 |
Toray Industries, Inc. |
Kompozycja leku do leczenia i/lub zapobiegania nowotworowi
|
|
RU2595400C2
(ru)
|
2011-08-04 |
2016-08-27 |
Торэй Индастриз, Инк. |
Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
|
|
EP2788378A4
(en)
*
|
2011-12-09 |
2015-09-09 |
Oncomed Pharm Inc |
COMBINATION THERAPY FOR CANCER TREATMENT
|
|
WO2013125654A1
(ja)
|
2012-02-21 |
2013-08-29 |
東レ株式会社 |
癌の治療及び／又は予防用医薬組成物
|
|
US9260513B2
(en)
|
2012-02-21 |
2016-02-16 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prevention of cancer
|
|
ES2739612T3
(es)
*
|
2012-02-21 |
2020-02-03 |
Toray Industries |
Composición farmacéutica para el tratamiento de cáncer
|
|
BR112014021103A2
(pt)
|
2012-02-21 |
2019-10-15 |
Toray Industries, Inc |
Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
|
|
BR112014024131A2
(pt)
*
|
2012-03-29 |
2017-07-25 |
Shire Human Genetic Therapies |
lipídios catiônicos ionizáveis
|
|
JP6107654B2
(ja)
|
2012-03-30 |
2017-04-05 |
東レ株式会社 |
肝臓癌の治療及び／又は予防用医薬組成物
|
|
WO2013147176A1
(ja)
|
2012-03-30 |
2013-10-03 |
東レ株式会社 |
胆嚢癌の治療及び／又は予防用医薬組成物
|
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
MX2015010854A
(es)
*
|
2013-03-14 |
2016-07-20 |
Genentech Inc |
Combinaciones de un compuesto inhibidor de mek con un compuesto inhibidor de her3/egfr y metodos de uso.
|
|
TN2015000444A1
(en)
*
|
2013-06-03 |
2017-04-06 |
Novartis Ag |
Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
|
|
AU2014303375B2
(en)
|
2013-08-09 |
2019-07-04 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prevention of cancer
|
|
EP3055290B1
(en)
|
2013-10-10 |
2019-10-02 |
Araxes Pharma LLC |
Inhibitors of kras g12c
|
|
GB201320729D0
(en)
|
2013-11-25 |
2014-01-08 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
EP3563870A1
(en)
*
|
2014-07-15 |
2019-11-06 |
F. Hoffmann-La Roche AG |
Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
|
WO2016193955A1
(en)
*
|
2015-06-04 |
2016-12-08 |
Giorgio Stassi |
Combinations of kinase inhibitors for treating colorectal cancer
|
|
LT3374359T
(lt)
|
2015-11-09 |
2020-03-25 |
Astrazeneca Ab |
Dihidroimidazopirazinono deriniai, tinkami panaudoti vėžio gydymui
|
|
KR20180081596A
(ko)
|
2015-11-16 |
2018-07-16 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
KR102444509B1
(ko)
|
2016-05-18 |
2022-09-19 |
미라티 테라퓨틱스, 인크. |
Kras g12c 억제제
|
|
US20180094322A1
(en)
*
|
2016-08-23 |
2018-04-05 |
The Trustees Of Columbia University In The City Of New York |
Biomarker for Predicting Colon Cancer Responsiveness to Anti-Tumor Treatment
|
|
JOP20190186A1
(ar)
|
2017-02-02 |
2019-08-01 |
Astellas Pharma Inc |
مركب كينازولين
|
|
EP3624896A4
(en)
*
|
2017-05-16 |
2021-03-31 |
Biomed Valley Discoveries, Inc. |
COMPOSITIONS AND METHODS OF TREATMENT OF CANCER WITH ATYPICAL BRAF MUTATIONS
|
|
LT3710439T
(lt)
|
2017-11-15 |
2023-05-10 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitoriai
|
|
MX2020005563A
(es)
|
2017-11-30 |
2020-10-28 |
Hanmi Pharm Ind Co Ltd |
Compuesto de tieno[3,2-d]pirimidina que tiene actividad inhibidora para proteina cinasa.
|
|
US10597405B2
(en)
|
2017-12-08 |
2020-03-24 |
Astrazeneca Ab |
Chemical compounds
|
|
CN111406448B
(zh)
|
2017-12-19 |
2021-12-14 |
株式会社富士 |
安装装置、检测装置及检测方法
|
|
HRP20230400T1
(hr)
|
2017-12-21 |
2023-06-23 |
Boehringer Ingelheim International Gmbh |
Benzilamino supstituirani piridopirimidinoni i derivati kao inhibitori sos1
|
|
AU2019242520B2
(en)
*
|
2018-03-30 |
2026-02-26 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prevention of cancer
|
|
EP3908283A4
(en)
|
2019-01-10 |
2022-10-12 |
Mirati Therapeutics, Inc. |
KRAS G12C INHIBITORS
|
|
CN114437065A
(zh)
|
2019-05-21 |
2022-05-06 |
益方生物科技(上海)股份有限公司 |
杂环化合物，其制备方法和用途
|
|
TW202110848A
(zh)
|
2019-05-24 |
2021-03-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用
|
|
EP3763711A1
(en)
|
2019-07-09 |
2021-01-13 |
Allinky Biopharma |
Tetrahydroisoquinoline compounds
|
|
CN112574207B
(zh)
|
2019-09-30 |
2023-04-11 |
南京药石科技股份有限公司 |
Erk1/2蛋白激酶抑制剂及其用途
|
|
CN112694475B
(zh)
|
2019-10-23 |
2025-09-23 |
苏州泽璟生物制药股份有限公司 |
环烷基类和杂环烷基类抑制剂及其制备方法和应用
|
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
|
WO2021109737A1
(zh)
|
2019-12-02 |
2021-06-10 |
上海璎黎药业有限公司 |
一种含氧杂环化合物、其制备方法及应用
|
|
WO2021113595A1
(en)
|
2019-12-06 |
2021-06-10 |
Beta Pharma, Inc. |
Phosphorus derivatives as kras inhibitors
|
|
KR102823105B1
(ko)
|
2019-12-06 |
2025-06-20 |
디3 바이오 (우씨) 컴퍼니, 리미티드 |
Erk 억제제로서 작용하는 스피로 화합물 및 이의 응용
|
|
CN112920183B
(zh)
|
2019-12-06 |
2024-07-19 |
南京圣和药业股份有限公司 |
作为kras-g12c抑制剂的化合物及其应用
|
|
JP7214925B2
(ja)
|
2019-12-06 |
2023-01-30 |
メッドシャイン ディスカバリー インコーポレイテッド |
Ｐａｎ－ＲＡＦキナーゼ阻害剤としてのビアリール化合物
|
|
PH12022551119A1
(en)
|
2019-12-10 |
2023-08-23 |
Hoffmann La Roche |
New methylquinazolinone derivatives
|
|
PT3886991T
(pt)
|
2019-12-11 |
2022-10-17 |
Lilly Co Eli |
Inibidores de kras g12c
|
|
IL293962B2
(en)
|
2019-12-19 |
2025-10-01 |
Jacobio Pharmaceuticals Co Ltd |
Mutant KRAS protein inhibitors
|
|
WO2021120890A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Pyrazolyl derivatives useful as anti-cancer agents
|
|
CN113045565A
(zh)
|
2019-12-27 |
2021-06-29 |
微境生物医药科技(上海)有限公司 |
新型K-Ras G12C抑制剂
|
|
JP7850663B2
(ja)
|
2019-12-27 |
2026-04-23 |
ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド |
スピロ環含有キナゾリン化合物
|
|
CA3175137A1
(en)
*
|
2020-03-12 |
2021-09-16 |
Toray Industries, Inc. |
Medicament for treatment and/or prevention of cancer
|
|
TW202144338A
(zh)
|
2020-04-08 |
2021-12-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
嘧啶并二環類衍生物、其製備方法及其在醫藥上的應用
|
|
WO2021216770A1
(en)
|
2020-04-22 |
2021-10-28 |
Accutar Biotechnology Inc. |
Substituted tetrahydroquinazoline compounds as kras inhibitors
|
|
CN115427414A
(zh)
|
2020-04-28 |
2022-12-02 |
贝达药业股份有限公司 |
稠环化合物及其在医药上的应用
|
|
CA3177261A1
(en)
|
2020-04-29 |
2021-11-04 |
Shanghai Ringene Biopharma Co., Ltd. |
Benzothiazolyl biaryl compound, and preparation method and use
|
|
CN115135636B
(zh)
|
2020-04-29 |
2024-08-23 |
北京泰德制药股份有限公司 |
喹喔啉酮衍生物作为kras g12c突变蛋白的不可逆抑制剂
|
|
CN115443274B
(zh)
|
2020-04-30 |
2025-04-25 |
勤浩医药（苏州）有限公司 |
含苯基并内磺酰胺的化合物
|
|
WO2021219072A1
(zh)
|
2020-04-30 |
2021-11-04 |
上海科州药物研发有限公司 |
作为kras抑制剂的杂环化合物的制备及其应用方法
|
|
CN115461342B
(zh)
|
2020-05-09 |
2025-02-21 |
正大天晴药业集团股份有限公司 |
含磷的sos1抑制剂
|
|
TWI799871B
(zh)
|
2020-05-27 |
2023-04-21 |
大陸商勁方醫藥科技(上海)有限公司 |
三環并環類化合物，其製法與醫藥上的用途
|
|
WO2021244603A1
(en)
|
2020-06-04 |
2021-12-09 |
Shanghai Antengene Corporation Limited |
Inhibitors of kras g12c protein and uses thereof
|
|
WO2021252339A1
(en)
|
2020-06-08 |
2021-12-16 |
Accutar Biotechnology, Inc. |
Substituted purine-2,6-dione compounds as kras inhibitors
|
|
WO2022002102A1
(en)
|
2020-06-30 |
2022-01-06 |
InventisBio Co., Ltd. |
Quinazoline compounds, preparation methods and uses thereof
|
|
WO2022017339A1
(zh)
|
2020-07-20 |
2022-01-27 |
江苏恒瑞医药股份有限公司 |
稠合哒嗪类衍生物、其制备方法及其在医药上的应用
|
|
EP4186903A4
(en)
|
2020-07-24 |
2024-08-07 |
Medshine Discovery Inc. |
Quinazoline compound
|
|
CN116194446A
(zh)
|
2020-08-06 |
2023-05-30 |
北京泰德制药股份有限公司 |
Sos1抑制剂、包含其的药物组合物及其用途
|
|
EP4204412A4
(en)
|
2020-08-26 |
2024-10-09 |
InventisBio Co., Ltd. |
HETEROARYL COMPOUNDS, PRODUCTION PROCESSES AND USES THEREOF
|